Novel nanocarrier delivered cancer chemotherapeutic agents

A cancer chemotherapeutic composition comprising:

• at least one chemotherapeutic agent derived from a nucleoside or a nucleobase;
• and
• a drug delivery system, wherein the chemotherapeutic agent is selected from the group consisting of:
• wherein x is one of O, NH, NR, or S;
• R1 is one of a methyl (“Me”), an ethyl (“Et”), an isopropyl (“i-Pr”), tert-butyl (“t-Bu”), neo-pentyl (“neo-Am”), n-hexane (“n-Hex”), cyclohexane (“Cy”), or
• wherein G1,2, Y1,2, and Z are each one of H, Cl, Br, I, methoxy (OMe), or an electron withdrawing group (EWG) that is selected from the group consisting of NO2, CN, CF3, COMe, SO2Me, CCR;
• R2 is one of i-Pr, t-Bu, neo-Am, n-Hex, Cy, or
• wherein G1,2, Y1,2, and Z are each one of H, Cl, Br, I, OMe, or an EWG that is selected from the group consisting of NO2, CN, CF3, COMe, SO2Me, CCR;
• and
• R3 is either H or

A nucleobase having is selected from the group consisting of:

• wherein x is one of O, NH, NR, or S;
• R1 is one of a methyl (“Me”), an ethyl (“Et”), an isopropyl (“i-Pr”), tert-butyl (“t-Bu”), neo-pentyl (“neo-Am”), n-hexane (“n-Hex”), cyclohexane (“Cy”), or
• wherein G1,2, Y1,2, and Z are each one of H, Cl, Br, I, methoxy (OMe), or an electron withdrawing group (EWG) that is selected from the group consisting of NO2, CN, CF3, COMe, SO2Me, CCR;
• R2 is one of i-Pr, t-Bu, neo-Am, n-Hex, Cy, or
• wherein G1,2, Y1,2, and Z are each one of H, Cl, Br, I, OMe, or an EWG that is selected from the group consisting of NO2, CN, CF3, COMe, SO2Me, CCR;
• and
• R3 is either H or